{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:48:13Z","timestamp":1761630493969,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.3816\/ccc.2008.n.020","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:06:38Z","timestamp":1221080798000},"page":"144-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer"],"prefix":"10.3816","volume":"7","author":[{"given":"M. Wasif","family":"Saif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter L.","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Israel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CCC.2008.n.020_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.020_bib2","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Eng J Med"},{"key":"10.3816\/CCC.2008.n.020_bib3","unstructured":"Hochster HS, Welles L, Hart L et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): preliminary results of the randomized \u201cTREE-2\u201d trial. Presented at: the 2005 American Society of Clinical Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 241."},{"key":"10.3816\/CCC.2008.n.020_bib4","doi-asserted-by":"crossref","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presented at: the 2005 American Society of Clinical Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL. Abstract 169a.","DOI":"10.1200\/jco.2005.23.16_suppl.2"},{"key":"10.3816\/CCC.2008.n.020_bib5","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2007.12.0949","article-title":"Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.020_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14740338.5.4.553","article-title":"Incidence and management of bevacizumabrelated toxicities in colorectal cancer","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.3816\/CCC.2008.n.020_bib7","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.020_bib8","first-page":"1019","article-title":"Clinical trials: referral resource: current clinical trials of the anti-VEGF monoclonal antibody bevacizumab","volume":"15","author":"Chen","year":"2001","journal-title":"Oncology"},{"issue":"suppl 11","key":"10.3816\/CCC.2008.n.020_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/sonc.2002.34053","article-title":"Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2\/neu protein and vascular endothelial growth factor","volume":"29","author":"Pegram","year":"2002","journal-title":"Semin Oncol"},{"key":"10.3816\/CCC.2008.n.020_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.3816\/CCC.2008.n.020_bib11","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.cad.0000231481.07654.fc","article-title":"Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response","volume":"17","author":"Gotlib","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CCC.2008.n.020_bib12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ctrv.2006.07.014","article-title":"Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?","volume":"32","author":"Azim","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CCC.2008.n.020_bib13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/ajhp\/62.10.1021","article-title":"Bevacizumab in combination chemotherapy for colorectal and other cancers","volume":"62","author":"Motl","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.3816\/CCC.2008.n.020_bib14","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1200\/JCO.2005.05.3728","article-title":"Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer","volume":"20","author":"Meyerhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CCC.2008.n.020_bib15","first-page":"118","article-title":"Role of panitumumab in the management of metastatic colorectal cancer","volume":"6","author":"Saif","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.3816\/CCC.2008.n.020_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14740338.6.2.175","article-title":"Incidence and management of cutaneous toxicities associated with cetuximab","volume":"6","author":"Saif","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.3816\/CCC.2008.n.020_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/1120009X.1994.11741178","article-title":"Dermatological toxicity from chemotherapy containing 5-fluorouracil","volume":"6","author":"Leo","year":"1994","journal-title":"J Chemother"},{"key":"10.3816\/CCC.2008.n.020_bib18","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811704121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002811704121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:00:28Z","timestamp":1761519628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002811704121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S1533002811704121"],"URL":"https:\/\/doi.org\/10.3816\/ccc.2008.n.020","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CCC.2008.n.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}